300723 一品红
已收盘 07-29 15:00:00
资讯
新帖
简况
一品红:截止2023年报披露日,公司共有各类在研项目133项,其中创新药项目7个
证券之星 · 07-29 17:01
一品红:截止2023年报披露日,公司共有各类在研项目133项,其中创新药项目7个
7月29日一品红跌17.33%,中信建投甄选混合A基金重仓该股
证券之星 · 07-29 16:21
7月29日一品红跌17.33%,中信建投甄选混合A基金重仓该股
子公司退回2.66亿,超一品红2023年净利润,还有何影响?
中新经纬 · 07-29 16:05
子公司退回2.66亿,超一品红2023年净利润,还有何影响?
石四药集团(02005.HK)曾急挫近19% 内地药企一品红涉集采违规
阿斯达克财经 · 07-29 15:25
石四药集团(02005.HK)曾急挫近19% 内地药企一品红涉集采违规
石四药集团大跌超18%,涉一品红2.66亿元国采退款
金融界 · 07-29 15:12
石四药集团大跌超18%,涉一品红2.66亿元国采退款
石四药集团一度大跌近20% 涉一品红2.66亿元国采退款
金融界 · 07-29 14:57
石四药集团一度大跌近20% 涉一品红2.66亿元国采退款
串通申报、 协商报价?一品红被罚2.66亿元,股价暴跌超17%
格隆汇 · 07-29 14:38
串通申报、 协商报价?一品红被罚2.66亿元,股价暴跌超17%
港股异动 | 石四药集团(02005)跌超15% 集采违约风暴引忧 一品红涉嫌围标串标被罚退回2.66亿
智通财经 · 07-29 14:18
港股异动 | 石四药集团(02005)跌超15% 集采违约风暴引忧 一品红涉嫌围标串标被罚退回2.66亿
集采史上金额最大违约!一品红股价暴跌17%
证券之星 · 07-29 13:59
集采史上金额最大违约!一品红股价暴跌17%
21健讯Daily|一品红全资子公司因集采违约需退回2.66亿元;方盛制药大股东减持
21财经网 · 07-29 08:15
21健讯Daily|一品红全资子公司因集采违约需退回2.66亿元;方盛制药大股东减持
一品红(300723.SZ)存在集采投标违约情形 将承担采购方所损失2.66亿元
智通财经网 · 07-28 21:33
一品红(300723.SZ)存在集采投标违约情形 将承担采购方所损失2.66亿元
集采违约!一品红要承担采购方损失,需退回2.66亿元金额
第一财经 · 07-28 13:45
集采违约!一品红要承担采购方损失,需退回2.66亿元金额
一品红:子公司一类创新药APH01727片获得临床试验批准
中国财富通 · 07-24
一品红:子公司一类创新药APH01727片获得临床试验批准
一品红(300723.SZ):一类创新药APH01727片获得临床试验批准
智通财经 · 07-24
一品红(300723.SZ):一类创新药APH01727片获得临床试验批准
一品红(300723)7月23日主力资金净卖出256.30万元
证券之星 · 07-24
一品红(300723)7月23日主力资金净卖出256.30万元
7月8日一品红发生1笔大宗交易 成交金额1.59亿元
证券之星 · 07-08
7月8日一品红发生1笔大宗交易 成交金额1.59亿元
一品红(300723.SZ)拟受让广州瑞安博24.05%股权 推动创新药AR882研发上市
智通财经 · 07-02
一品红(300723.SZ)拟受让广州瑞安博24.05%股权 推动创新药AR882研发上市
一品红最新公告:瑞奥生物拟1000万美元受让广州瑞安博24.05%股权
证券之星 · 07-02
一品红最新公告:瑞奥生物拟1000万美元受让广州瑞安博24.05%股权
一品红(300723.SZ)子公司获得奥美沙坦酯口崩片注册证书
智通财经 · 07-01
一品红(300723.SZ)子公司获得奥美沙坦酯口崩片注册证书
一品红(300723.SZ)子公司获得非诺贝特酸胆碱缓释胶囊药品补充申请批准通知书
智通财经 · 07-01
一品红(300723.SZ)子公司获得非诺贝特酸胆碱缓释胶囊药品补充申请批准通知书
暂无数据
公司概况
公司名称:
一品红药业股份有限公司
所属行业:
医药制造业
上市日期:
2017-11-16
主营业务:
一品红药业股份有限公司主营业务为处方药研发、生产和销售,主要产品有儿童药和慢病药。公司具备强劲的研发创新能力及转化能力,公司充分发挥企业优势,通过自主研发、技术合作等多种创新方式,不断提高公司医药研发实力;目前公司荣获中国化药研发综合实力百强企业、中国创新力医药企业100强和中国化药企业百强企业等荣誉称号。报告期内,一品红研发数字化管理平台凭借对企业研发项目全过程的有力支撑及高效协同,荣获中国企业数字化联盟全国医药大健康CIO大会组委会颁发的2023全国医药行业优秀数字化案例奖。公司生物疫苗开发平台荣获国家知识产权局“中国专利奖优秀奖”。
发行价格:
17.05
{"stockData":{"symbol":"300723","market":"SZ","secType":"STK","nameCN":"一品红","latestPrice":15.5,"timestamp":1722236628000,"preClose":18.75,"halted":0,"volume":12421211,"delay":0,"floatShares":418000000,"shares":454000000,"eps":0.3832,"marketStatus":"已收盘","marketStatusCode":5,"change":-3.25,"latestTime":"07-29 15:00:00","open":15.3,"high":16.6,"low":15.09,"amount":193000000,"amplitude":0.0805,"askPrice":15.51,"askSize":297,"bidPrice":15.5,"bidSize":187,"shortable":0,"etf":0,"ttmEps":0.3832,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1722303000000},"adr":0,"adjPreClose":18.75,"symbolType":"stock","openAndCloseTimeList":[[1722216600000,1722223800000],[1722229200000,1722236400000]],"highLimit":20.63,"lowLimit":16.88,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":454143281,"pbRate":3.25,"roa":"--","roe":"3.93%","epsLYR":0.42,"committee":-0.221684,"marketValue":7039000000,"floatMarketCap":6474000000,"peRate":40.448853,"changeRate":-0.1733,"turnoverRate":0.0297,"status":1},"requestUrl":"/m/hq/s/300723/tweets","defaultTab":"tweets","newsList":[{"id":"2455661639","title":"一品红:截止2023年报披露日,公司共有各类在研项目133项,其中创新药项目7个","url":"https://stock-news.laohu8.com/highlight/detail?id=2455661639","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2455661639?lang=zh_cn&edition=full","pubTime":"2024-07-29 17:01","pubTimestamp":1722243711,"startTime":"0","endTime":"0","summary":"截止2023年报披露日,公司共有各类在研项目133项,其中创新药项目7个。7月,公司自主研发的一类创新药 APH01727片针对体重管理及2型糖尿病的临床试验获批,并收到《药物临床试验批准通知书》,将于近期开展临床试验。2024年4月,公司发布了新一期的员工持股计划。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072900025206.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239","BK1574","06978","BK1161","159992"],"gpt_icon":0},{"id":"2455263316","title":"7月29日一品红跌17.33%,中信建投甄选混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2455263316","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2455263316?lang=zh_cn&edition=full","pubTime":"2024-07-29 16:21","pubTimestamp":1722241292,"startTime":"0","endTime":"0","summary":"证券之星消息,7月29日一品红跌17.33%创60日新低,收盘报15.5元,换手率2.94%,成交量12.42万手,成交额1.93亿元。根据2024基金半年报公募基金重仓股数据,重仓该股的公募基金共8家,其中持有数量最多的公募基金为中信建投甄选混合A。中信建投甄选混合A目前规模为4.9亿元,最新净值1.7622,较上一交易日上涨1.25%,近一年下跌13.1%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072900022291.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601066","300723","BK0239","BK0276"],"gpt_icon":0},{"id":"2455633851","title":"子公司退回2.66亿,超一品红2023年净利润,还有何影响?","url":"https://stock-news.laohu8.com/highlight/detail?id=2455633851","media":"中新经纬","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2455633851?lang=zh_cn&edition=full","pubTime":"2024-07-29 16:05","pubTimestamp":1722240327,"startTime":"0","endTime":"0","summary":"(王玉玲 林琬斯)近日,一品红发布公告称,全资子公司广州一品红制药有限公司(下称...","market":"hk","thumbnail":"http://www.jwview.com/jingwei/07-29/U820P902T1D601926F10DT20240729160527.jpg","type":0,"news_type":0,"thumbnails":["http://www.jwview.com/jingwei/07-29/U820P902T1D601926F10DT20240729160527.jpg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.jwview.com/jingwei/html/07-29/601926.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zxjw_stock","symbols":["300723"],"gpt_icon":0},{"id":"2455687620","title":"石四药集团(02005.HK)曾急挫近19% 内地药企一品红涉集采违规","url":"https://stock-news.laohu8.com/highlight/detail?id=2455687620","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2455687620?lang=zh_cn&edition=full","pubTime":"2024-07-29 15:25","pubTimestamp":1722237900,"startTime":"0","endTime":"0","summary":"石四药集团今日平开后跌幅逐步扩大,午后低见3.5元,一度跌18.6%,见2022年11月以来新低。内地药企一品红日前公告指,收到国家组织药品联合采购办公室的违约通知书,因在第七批国家组织药品集中带量采购盐酸溴己新注射液投标中,存在违规行为,被责令退回采购方2.66亿元人民币,是集采史上已公开涉及金额最大违约案例。内媒报道,中标盐酸溴己新注射液品种的公司,除了一品红制药外,亦包括石四药集团旗下石家庄四药有限公司等。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220419120908466_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220419120908466_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1367078/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02005","BK0239","BK1191","300723"],"gpt_icon":0},{"id":"2455823666","title":"石四药集团大跌超18%,涉一品红2.66亿元国采退款","url":"https://stock-news.laohu8.com/highlight/detail?id=2455823666","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2455823666?lang=zh_cn&edition=full","pubTime":"2024-07-29 15:12","pubTimestamp":1722237146,"startTime":"0","endTime":"0","summary":"石四药集团(2005.HK)盘中一度跌超18%至3.5港元,股价创2022年11月以来新低。消息面上,日前,一品红因在第七批国采盐酸溴己新注射液投标中存在违规行为,被联采办下发违约通知书,需退回2.66亿元。截止目前,这是集采史上已公开涉及金额最大违约案例。当时,与一品红同时中标的还有石四药集团旗下石家庄四药有限公司、仁合益康集团有限公司、成都欣捷高新技术开发股份有限公司。\n\n\r\n 责任编辑:安东","market":"sh","thumbnail":"http://imgcloud.jrjimg.cn/2024/07/cms_20240729151227093.jpg","type":0,"news_type":0,"thumbnails":["http://imgcloud.jrjimg.cn/2024/07/cms_20240729151227093.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/29151241869433.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1191","300723","BK0239","02005"],"gpt_icon":0},{"id":"2455386684","title":"石四药集团一度大跌近20% 涉一品红2.66亿元国采退款","url":"https://stock-news.laohu8.com/highlight/detail?id=2455386684","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2455386684?lang=zh_cn&edition=full","pubTime":"2024-07-29 14:57","pubTimestamp":1722236233,"startTime":"0","endTime":"0","summary":"石四药集团(02005.HK)午后一度跌近20%,截至发稿跌14%,报3.67港元,成交额超8000万港元。消息面上,日前,一品红因在第七批国采盐酸溴己新注射液投标中存在违规行为,被联采办下发违约通知 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20240729/c660242777.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2455681851","title":"串通申报、 协商报价?一品红被罚2.66亿元,股价暴跌超17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2455681851","media":"格隆汇","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2455681851?lang=zh_cn&edition=full","pubTime":"2024-07-29 14:38","pubTimestamp":1722235108,"startTime":"0","endTime":"0","summary":"变身“一抹黑”","market":"sg","thumbnail":"https://img3.gelonghui.com/8f1b6-31a98bd2-acf1-40b9-88e4-fa98c1183f0c.jpg?guru_height=853&guru_width=1280","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/8f1b6-31a98bd2-acf1-40b9-88e4-fa98c1183f0c.jpg?guru_height=853&guru_width=1280"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/886937","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2455689326","title":"港股异动 | 石四药集团(02005)跌超15% 集采违约风暴引忧 一品红涉嫌围标串标被罚退回2.66亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2455689326","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2455689326?lang=zh_cn&edition=full","pubTime":"2024-07-29 14:18","pubTimestamp":1722233885,"startTime":"0","endTime":"0","summary":"消息面上,一品红日前公告称收到国家组织药品联合采购办公室的违约通知书,因在第七批国家组织药品集中带量采购盐酸溴己新注射液投标中存在违规行为,被责令退回采购方2.66亿元。截止目前,一品红是集采史上已公开涉及金额最大违约案例。据悉,一品红携盐酸溴己新注射液于2022年7月参与第七批国家药品集采,以17.88元的中标价,获得22%的约定采购额度。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1156721.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK0239","02005","300723"],"gpt_icon":0},{"id":"2455685022","title":"集采史上金额最大违约!一品红股价暴跌17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2455685022","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2455685022?lang=zh_cn&edition=full","pubTime":"2024-07-29 13:59","pubTimestamp":1722232742,"startTime":"0","endTime":"0","summary":"近日,一品红因围标串标行为被国家组织药品联合采购办公室下发违约通知书,成为集采史上金额最大的违约案例。截至发稿,一品红跌幅超17%,几度接近跌停。据测算,一品红制药的违约行为给采购方造成了约2.66亿元的损失。一品红制药将按照约定,全额退回该损失金额。值得注意的是,此前,今年4月17日,国家组织药品联合采购办公室曾发布公告,约谈部分价格异常品种投标企业,其中包括一品红制药参与的溴己新注射液。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2024072900012922.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2455402571","title":"21健讯Daily|一品红全资子公司因集采违约需退回2.66亿元;方盛制药大股东减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2455402571","media":"21财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2455402571?lang=zh_cn&edition=full","pubTime":"2024-07-29 08:15","pubTimestamp":1722212153,"startTime":"0","endTime":"0","summary":"舆情预警一品红全资子公司收到集采违约通知7月27日,一品红药业股份有限公司公告称,其全资子公司广州一品红制药有限公司收到国家组织药品联合采购办公室的违约通知书。据一品红制药的销售数据测算,此次违约行为造成采购方损失人民币266,443,608.00元,一品红制药将严格按照相关约定,将损失金额全部退回。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407290815589563cc28&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407290815589563cc28&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","603998","300723","BK0060"],"gpt_icon":0},{"id":"2454523926","title":"一品红(300723.SZ)存在集采投标违约情形 将承担采购方所损失2.66亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2454523926","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454523926?lang=zh_cn&edition=full","pubTime":"2024-07-28 21:33","pubTimestamp":1722173630,"startTime":"0","endTime":"0","summary":"智通财经APP讯,一品红 发布公告,公司全资子公司广州一品红制药有限公司于近日收到国家组织药品联合采购办公室的违约通知书文。按照一品红制药的销售数据测算,上述违约行为造成采购方损失人民币2.66亿元。一品红制药将严格按照相关约定,将损失金额全部退回。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1156552.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2454751294","title":"集采违约!一品红要承担采购方损失,需退回2.66亿元金额","url":"https://stock-news.laohu8.com/highlight/detail?id=2454751294","media":"第一财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454751294?lang=zh_cn&edition=full","pubTime":"2024-07-28 13:45","pubTimestamp":1722145500,"startTime":"0","endTime":"0","summary":"按照一品红制药的销售数据测算,上述违约行为造成采购方损失人2.66亿元。 这一次,一品红制药要退回2.66亿元金额,对于一品红而言,有些得不偿失。 一品红在7月27日的公告中表示,上述违约退回金额是根据一品红制药2022年至今盐酸溴己新注射液的销售数据测算的,对公司相关年度财务造成的影响尚不确定,公司将积极与会计师做好沟通确认,最终以经审计的结果为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2024-07-28/doc-incfsfxy3182132.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2024-07-28/doc-incfsfxy3182132.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2453228023","title":"一品红:子公司一类创新药APH01727片获得临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2453228023","media":"中国财富通","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453228023?lang=zh_cn&edition=full","pubTime":"2024-07-24 14:37","pubTimestamp":1721803040,"startTime":"0","endTime":"0","summary":"中国财富通7月24日 - 一品红(300723)公告称,近日,公司全资子公司广州一品红制药有限公司自主研发的一类创新药物APH01727片的药物临床试验申请已获得国家药品监督管理局批准,并收到《药物临床试验批准通知书》,将于近期开展临床试验。该药品拟用于2型糖尿病、超重/肥胖患者的治疗。APH01727片获得临床试验批准对公司短期的财务状况、经营业绩不构成重大影响。该产品需要按国家药品注册相关规定要求开展临床试验,待临床试验成功后按法定程序申报生产。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=gASZVrxQLq4%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159992","BK1583","BK1141","03347","BK1161","300723","BK0239","BK1574","BK1576","06978"],"gpt_icon":0},{"id":"2453049850","title":"一品红(300723.SZ):一类创新药APH01727片获得临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2453049850","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453049850?lang=zh_cn&edition=full","pubTime":"2024-07-24 11:59","pubTimestamp":1721793584,"startTime":"0","endTime":"0","summary":"智通财经APP讯,一品红(300723.SZ)公告,公司全资子公司广州一品红制药有限公司(简称“一品红制药”)自主研发的一类创新药物APH01727片的药物临床试验申请已获得国家药品监督管理局批准,并收到《药物临床试验批准通知书》,将于近期开展临床试验。根据《中华人民共和国药品管理法》及有关规定,经审查,2024年5月13日受理的APH01727片临床试验申请符合药品注册的有关要求,同意本品开展体重管理适应症临床试验。根据《中华人民共和国药品管理法》及有关规定,经审查,2024年5月13日受理的APH01727片临床试验申请符合药品注册的有关要求,同意本品开展2型糖尿病的临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1154847.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1576","BK1574","BK1141","300723","BK0239","BK1583","159992","BK1161","03347","06978"],"gpt_icon":0},{"id":"2453201983","title":"一品红(300723)7月23日主力资金净卖出256.30万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2453201983","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453201983?lang=zh_cn&edition=full","pubTime":"2024-07-24 09:19","pubTimestamp":1721783980,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年7月23日收盘,一品红报收于18.87元,下跌4.79%,换手率0.57%,成交量2.43万手,成交额4646.5万元。7月23日的资金流向数据方面,主力资金净流出256.3万元,占总成交额5.52%,游资资金净流入476.93万元,占总成交额10.26%,散户资金净流出220.63万元,占总成交额4.75%。融券方面,融券卖出1.36万股,融券偿还3600.0股,融券余量19.97万股,融券余额376.92万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072400016908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2449872623","title":"7月8日一品红发生1笔大宗交易 成交金额1.59亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2449872623","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449872623?lang=zh_cn&edition=full","pubTime":"2024-07-08 16:40","pubTimestamp":1720428044,"startTime":"0","endTime":"0","summary":"证券之星消息,7月8日一品红发生大宗交易,交易数据如下:大宗交易成交价格17.49元,相对当日收盘价折价9.98%,成交908.28万股,成交金额15885.8万元,买方营业部为国泰君安证券股份有限公司深圳龙华壹成中心证券营业部,卖方营业部为广发证券股份有限公司广州农林下路证券营业部。近三个月该股共发生1笔大宗交易,合计成交9.08万手,折价成交1笔。截至2024年7月8日收盘,一品红报收于19.43元,下跌2.41%,换手率0.47%,成交量1.98万手,成交额3870.44万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070800021254.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2448138604","title":"一品红(300723.SZ)拟受让广州瑞安博24.05%股权 推动创新药AR882研发上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2448138604","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448138604?lang=zh_cn&edition=full","pubTime":"2024-07-02 17:20","pubTimestamp":1719912031,"startTime":"0","endTime":"0","summary":"智通财经APP讯,一品红(300723.SZ)公告,公司拟受让控股子公司广州瑞安博少数股东部分股权,由公司全资子公司瑞奥生物以自有资金1000万美元受让控股子公司广州瑞安博少数股东Arthrosi 24.05%的股权,并签订《股权转让协议》。交易完成后,公司全资子公司瑞奥生物持有广州瑞安博的股权比例将从60.70%上升至84.75%,广州瑞安博仍为公司控股子公司。据悉,该事项旨在推动创新药AR882高效研发和快速上市,进一步提高公司核心竞争力和综合竞争优势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1144368.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4171","06978","BK4224","300723","BK0239","BK1574","BK4588","BK4567","159992","BK4585","PLD","BK1161","BK4534"],"gpt_icon":0},{"id":"2448385521","title":"一品红最新公告:瑞奥生物拟1000万美元受让广州瑞安博24.05%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2448385521","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448385521?lang=zh_cn&edition=full","pubTime":"2024-07-02 17:09","pubTimestamp":1719911379,"startTime":"0","endTime":"0","summary":"一品红公告,瑞奥生物拟以自有资金1000万美元(折合人民币约7268万元)受让公司控股子公司广州瑞安博少数股东Arthrosi24.05%的股权。本次交易完成后,公司全资子公司瑞奥生物持有广州瑞安博的股权比例将由60.70%上升至84.75%,广州瑞安博仍为公司控股子公司。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070200026889.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"gpt_icon":0},{"id":"2448937797","title":"一品红(300723.SZ)子公司获得奥美沙坦酯口崩片注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2448937797","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448937797?lang=zh_cn&edition=full","pubTime":"2024-07-01 11:54","pubTimestamp":1719806066,"startTime":"0","endTime":"0","summary":"智通财经APP讯,一品红(300723.SZ)发布公告,公司全资子公司广州一品红制药有限公司于近日收到国家药品监督管理局核准签发的关于奥美沙坦酯口崩片的《药品注册证书》,奥美沙坦酯口崩片适用于高血压的治疗。此次获得奥美沙坦酯口崩片注册证书,标志着公司具备了在国内市场生产销售该药品的资格,将进一步丰富了公司在慢病领域治疗的产品管线和品类,增强公司在慢病药领域的竞争力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1143450.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300723","BK0239"],"gpt_icon":0},{"id":"2448400937","title":"一品红(300723.SZ)子公司获得非诺贝特酸胆碱缓释胶囊药品补充申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2448400937","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448400937?lang=zh_cn&edition=full","pubTime":"2024-07-01 11:52","pubTimestamp":1719805937,"startTime":"0","endTime":"0","summary":"智通财经APP讯,一品红 发布公告,公司全资子公司广州市联瑞制药有限公司于近日收到国家药品监督管理局核准签发的关于非诺贝特酸胆碱缓释胶囊的《药品补充申请批准通知书》。此次公司新增获得非诺贝特酸胆碱缓释胶囊药品补充申请批准通知书,标志着公司具备了在国内市场销售该规格药品的资格,将进一步增强公司在慢病药领域的竞争力,对公司业绩产生积极影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1143449.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","300723"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2017-11-16","address":"广东省广州市黄埔区广州国际生物岛寰宇一路27号云润大厦17层","stockEarnings":[{"period":"1week","weight":-0.218},{"period":"1month","weight":-0.2112},{"period":"3month","weight":-0.312},{"period":"6month","weight":-0.2319},{"period":"1year","weight":-0.4309},{"period":"ytd","weight":-0.4755}],"companyName":"一品红药业股份有限公司","boardCode":"AI0027","perCapita":"31824股","boardName":"医药制造业","registeredCapital":"45414万元","compareEarnings":[{"period":"1week","weight":-0.0244},{"period":"1month","weight":-0.0255},{"period":"3month","weight":-0.0686},{"period":"6month","weight":0.037},{"period":"1year","weight":-0.1172},{"period":"ytd","weight":-0.0279}],"survey":" 一品红药业股份有限公司主营业务为处方药研发、生产和销售,主要产品有儿童药和慢病药。公司具备强劲的研发创新能力及转化能力,公司充分发挥企业优势,通过自主研发、技术合作等多种创新方式,不断提高公司医药研发实力;目前公司荣获中国化药研发综合实力百强企业、中国创新力医药企业100强和中国化药企业百强企业等荣誉称号。报告期内,一品红研发数字化管理平台凭借对企业研发项目全过程的有力支撑及高效协同,荣获中国企业数字化联盟全国医药大健康CIO大会组委会颁发的2023全国医药行业优秀数字化案例奖。公司生物疫苗开发平台荣获国家知识产权局“中国专利奖优秀奖”。","serverTime":1722277306674,"listedPrice":17.05,"stockholders":"13124人(较上一季度减少3.31%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"一品红(300723)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供一品红(300723)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"一品红,300723,一品红股票,一品红股票老虎,一品红股票老虎国际,一品红行情,一品红股票行情,一品红股价,一品红股市,一品红股票价格,一品红股票交易,一品红股票购买,一品红股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"一品红(300723)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供一品红(300723)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}